Advertisement

Geriatric screening tools predict survival outcomes in older patients with diffuse large B cell lymphoma

  • Masatoshi Sakurai
  • Daiki Karigane
  • Hidenori Kasahara
  • Tomohiko Tanigawa
  • Akaru Ishida
  • Hiroshi Murakami
  • Masao Kikuchi
  • Sumiko Kohashi
Original Article
  • 66 Downloads

Abstract

The proportion of elderly patients with diffuse large B cell lymphoma (DLBCL) appears to be increasing, with outcomes varying widely because of the patients’ heterogeneity. Geriatric assessment is used to predict prognosis in elderly patients with DLBCL, but the utility of two simple screening tools for patients with DLBCL, the Flemish version of the Triage Risk Screening Tool (fTRST) and G8, has remained to be elucidated. We retrospectively assessed patients using fTRST and G8, and evaluated the impacts of the scores on survival outcomes in older patients with newly diagnosed DLBCL. A total of 59 patients aged 65 years or older and who were diagnosed with DLBCL were included. The median age was 77 years (range, 65–91 years), and the initial treatments were R-CHOP (63%) and R-THPCOP (31%). The estimated 2-year overall survival (OS) rate was significantly lower in patients with abnormal fTRST scores (≥ 2; N = 17) than in those with normal fTRST scores (< 2; N = 42): (50.5% (95% CI, 22.7–73.0%) vs. 82.2% (95% CI, 63.8–91.8%), P = 0.007). The estimated 2-year OS rate was significantly lower also in patients with abnormal G8 scores (≤ 14; N = 38) than in those with normal G8 scores (> 14; N = 21): (66.1% (95% CI, 46.7–79.5%) vs. 86.8% (95% CI, 55.7–96.7%), P = 0.03, respectively). These associations were independently significant after adjusting for other significant factors by multivariate analysis. These results suggest that the easy-to-use geriatric screening tools, fTRST and G8, have strong prognostic value for OS in older patients with DLBCL.

Keywords

Diffuse large B cell lymphoma Geriatric screening tools Older patients Prognosis 

Notes

Acknowledgments

The authors would like to thank all paramedic staff members at Tachikawa Hospital for their excellent care of the patients and their families.

Compliance with ethical standards

Conflicts of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. For this type of study, formal consent is not required.

Informed consent

The study was approved by the ethics boards of the institution.

References

  1. 1.
    Lymphoma Study Group of Japanese Pathologists (2000) The World Health Organization classification of malignant lymphomas in Japan: incidence of recently recognized entities. Pathol Int 50:696–702CrossRefGoogle Scholar
  2. 2.
    Smith A, Howell D, Patmore R, Jack A, Roman E (2011) Incidence of haematological malignancy by sub-type: a report from the Haematological malignancy research network. Br J Cancer 105:1684–1692CrossRefGoogle Scholar
  3. 3.
    Coiffier B, Lepage E, Briere J et al (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235–242CrossRefGoogle Scholar
  4. 4.
    Peyrade F, Jardin F, Thieblemont C, Thyss A, Emile JF, Castaigne S, Coiffier B, Haioun C, Bologna S, Fitoussi O, Lepeu G, Fruchart C, Bordessoule D, Blanc M, Delarue R, Janvier M, Salles B, André M, Fournier M, Gaulard P, Tilly H (2011) Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 12:460–468CrossRefGoogle Scholar
  5. 5.
    Wildiers H, Heeren P, Puts M, Topinkova E, Janssen-Heijnen MLG, Extermann M, Falandry C, Artz A, Brain E, Colloca G, Flamaing J, Karnakis T, Kenis C, Audisio RA, Mohile S, Repetto L, van Leeuwen B, Milisen K, Hurria A (2014) International Society of Geriatric Oncology consensus on geriatric assessment in older patients with cancer. J Clin Oncol 32:2595–2603CrossRefGoogle Scholar
  6. 6.
    Audisio RA, Pope D, Ramesh HS et al (2008) Shall we operate? Preoperative assessment in elderly cancer patients (PACE) can help. A SIOG surgical task force prospective study. Crit Rev Oncol Hematol 65:156–163CrossRefGoogle Scholar
  7. 7.
    Hurria A, Togawa K, Mohile SG, Owusu C, Klepin HD, Gross CP, Lichtman SM, Gajra A, Bhatia S, Katheria V, Klapper S, Hansen K, Ramani R, Lachs M, Wong FL, Tew WP (2011) Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. J Clin Oncol 29:3457–3465CrossRefGoogle Scholar
  8. 8.
    Merli F, Luminari S, Rossi G, Mammi C, Marcheselli L, Ferrari A, Spina M, Tucci A, Stelitano C, Capodanno I, Fragasso A, Baldini L, Bottelli C, Montechiarello E, Fogazzi S, Lamorgese C, Cavalli L, Federico M, for the Fondazione Italiana Linfomi (2014) Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by comprehensive geriatric assessment: results from a study of the Fondazione Italiana Linfomi. Leuk Lymphoma 55:38–43CrossRefGoogle Scholar
  9. 9.
    Spina M, Balzarotti M, Uziel L, Ferreri AJM, Fratino L, Magagnoli M, Talamini R, Giacalone A, Ravaioli E, Chimienti E, Berretta M, Lleshi A, Santoro A, Tirelli U (2012) Modulated chemotherapy according to modified comprehensive geriatric assessment in 100 consecutive elderly patients with diffuse large B-cell lymphoma. Oncologist 17:838–846CrossRefGoogle Scholar
  10. 10.
    Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G (2009) A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 115:4547–4553CrossRefGoogle Scholar
  11. 11.
    Braes T, Flamaing J, Sterckx W, Lipkens P, Sabbe M, de Rooij SE, Schuurmans MJ, Moons P, Milisen K (2009) Predicting the risk of functional decline in older patients admitted to the hospital: a comparison of three screening instruments. Age Ageing 38:600–603CrossRefGoogle Scholar
  12. 12.
    Meldon SW, Mion LC, Palmer RM et al (2003) A brief risk-stratification tool to predict repeat emergency department visits and hospitalizations in older patients discharged from the emergency department. Acad Emerg Med 10:224–232CrossRefGoogle Scholar
  13. 13.
    Bellera CA, Rainfray M, Mathoulin-Pelissier S, Mertens C, Delva F, Fonck M, Soubeyran PL (2012) Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Ann Oncol 23:2166–2172CrossRefGoogle Scholar
  14. 14.
    Soubeyran P, Bellera C, Goyard J, Heitz D, Curé H, Rousselot H, Albrand G, Servent V, Jean OS, van Praagh I, Kurtz JE, Périn S, Verhaeghe JL, Terret C, Desauw C, Girre V, Mertens C, Mathoulin-Pélissier S, Rainfray M (2014) Screening for vulnerability in older cancer patients: the ONCODAGE prospective multicenter cohort study. PLoS One 9:e115060CrossRefGoogle Scholar
  15. 15.
    Mohile SG, Bylow K, Dale W, Dignam J, Martin K, Petrylak DP, Stadler WM, Rodin M (2007) A pilot study of the vulnerable elders survey-13 compared with the comprehensive geriatric assessment for identifying disability in older patients with prostate cancer who receive androgen ablation. Cancer 109:802–810CrossRefGoogle Scholar
  16. 16.
    Saliba D, Elliott M, Rubenstein LZ, Solomon DH, Young RT, Kamberg CJ, Carol Roth RN, MacLean CH, Shekelle PG, Sloss EM, Wenger NS (2001) The vulnerable elders survey: a tool for identifying vulnerable older people in the community. J Am Geriatr Soc 49:1691–1699CrossRefGoogle Scholar
  17. 17.
    Kenis C, Decoster L, Van Puyvelde K et al (2014) Performance of two geriatric screening tools in older patients with cancer. J Clin Oncol 32:19–26CrossRefGoogle Scholar
  18. 18.
    Hamaker ME, Mitrovic M, Stauder R (2014) The G8 screening tool detects relevant geriatric impairments and predicts survival in elderly patients with a haematological malignancy. Ann Hematol 93:1031–1040CrossRefGoogle Scholar
  19. 19.
    Hara T, Yoshikawa T, Goto H, Sawada M, Yamada T, Fukuno K, Kasahara S, Shibata Y, Matsumoto T, Mabuchi R, Nakamura N, Nakamura H, Ninomiya S, Kitagawa J, Kanemura N, Nannya Y, Katsumura N, Takahashi T, Kito Y, Takami T, Miyazaki T, Takeuchi T, Shimizu M, Tsurumi H (2018) R-THP-COP versus R-CHOP in patients younger than 70 years with untreated diffuse large B cell lymphoma: a randomized, open-label, noninferiority phase 3 trial. Hematol Oncol 36:638–644.  https://doi.org/10.1002/hon.2524 CrossRefPubMedGoogle Scholar
  20. 20.
    Tsurumi H, Hara T, Goto N, Kanemura N, Kasahara S, Sawada M, Yasuda I, Yamada T, Shimizu M, Takami T, Moriwaki H (2007) A phase II study of a THP-COP regimen for the treatment of elderly patients aged 70 years or older with diffuse large B-cell lymphoma. Hematol Oncol 25:107–114CrossRefGoogle Scholar
  21. 21.
    Laribi K, Denizon N, Bolle D, Truong C, Besançon A, Sandrini J, Anghel A, Farhi J, Ghnaya H, Baugier de Materre A (2016) R-CVP regimen is active in frail elderly patients aged 80 or over with diffuse large B cell lymphoma. Ann Hematol 95:1705–1714CrossRefGoogle Scholar
  22. 22.
    Hirakawa T, Yamaguchi H, Yokose N, Gomi S, Inokuchi K, Dan K (2010) Importance of maintaining the relative dose intensity of CHOP-like regimens combined with rituximab in patients with diffuse large B-cell lymphoma. Ann Hematol 89:897–904CrossRefGoogle Scholar
  23. 23.
    Gordon M (2014) Manual of nursing diagnosis. Jones & Bartlett Learning, MassachusettsGoogle Scholar
  24. 24.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383CrossRefGoogle Scholar
  25. 25.
    Kanda Y (2013) Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant 48:452–458CrossRefGoogle Scholar
  26. 26.
    Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 107:265–276CrossRefGoogle Scholar
  27. 27.
    Chihara D, Westin JR, Oki Y, Ahmed MA, Do B, Fayad LE, Hagemeister FB, Romaguera JE, Fanale MA, Lee HJ, Turturro F, Samaniego F, Neelapu SS, Rodriguez MA, Fowler NH, Wang M, Davis RE, Nastoupil LJ (2016) Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma. Cancer 122:3145–3151CrossRefGoogle Scholar
  28. 28.
    Bairey O, Benjamini O, Blickstein D, Elis A, Ruchlemer R (2006) Non-Hodgkin's lymphoma in patients 80 years of age or older. Ann Oncol 17:928–934CrossRefGoogle Scholar
  29. 29.
    Thieblemont C, Grossoeuvre A, Houot R et al (2008) Non-Hodgkin’s lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19:774–779CrossRefGoogle Scholar
  30. 30.
    Eyre TA, Salisbury R, Eyre DW, Watson C, Collins GP, Hatton CS (2016) Results of a large retrospective analysis of the effect of intended dose intensity of R-CHOP on outcome in a cohort of consecutive, unselected elderly patients with de novo diffuse large B cell lymphoma. Br J Haematol 173:487–491CrossRefGoogle Scholar
  31. 31.
    Merli F, Luminari S, Rossi G et al (2012) Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly “fit” patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi. Leuk Lymphoma 53:581–588CrossRefGoogle Scholar
  32. 32.
    Beygi S, Sadashiv S, Reilly JB, Khan C, Lister J (2018) Frontline treatment of diffuse large B-cell lymphoma in elderly: a systematic review of clinical trials in post-rituximab era. Leuk Lymphoma 4:1–15CrossRefGoogle Scholar
  33. 33.
    Shimoyama Y, Yamamoto K, Asano N, Oyama T, Kinoshita T, Nakamura S (2008) Age-related Epstein-Barr virus-associated B-cell lymphoproliferative disorders: special references to lymphomas surrounding this newly recognized clinicopathologic disease. Cancer Sci 99:1085–1091CrossRefGoogle Scholar
  34. 34.
    Peyrade F, Gastaud L, Re D, Pacquelet-Cheli S, Thyss A (2012) Treatment decisions for elderly patients with haematological malignancies: a dilemma. Lancet Oncol 13:e344–e352CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of HematologyFederation of National Public Service Personnel Mutual Aid Associations Tachikawa HospitalTachikawa-shiJapan

Personalised recommendations